Welcome to our dedicated page for Strata Skin Sciences SEC filings (Ticker: SSKN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The STRATA Skin Sciences, Inc. (NASDAQ: SSKN) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing a structured view of how this medical technology issuer reports its operations, governance, and capital activities. As a Nasdaq-listed manufacturer of in-office dermatologic devices such as the XTRAC® excimer laser, VTRAC® lamp systems, and TheraClearX® Acne Therapy System, STRATA uses its SEC filings to detail financial performance, risk factors, reimbursement developments, and strategic initiatives.
Core periodic reports like the Form 10-K annual report and Form 10-Q quarterly reports contain audited and interim financial statements, segment information for dermatology recurring procedures and equipment, and management’s discussion of trends in recurring billings, equipment revenue, and margins. These filings also discuss dependencies on reimbursement under CPT® codes 96920–96922 for excimer laser procedures and outline key risks related to payer policies, clinical adoption, and competition in dermatology devices.
Current reports on Form 8-K provide more immediate insight into material events. STRATA has filed 8-Ks to announce quarterly financial results, registered direct offerings, at-the-market equity distribution arrangements, Nasdaq listing compliance notices, and investor presentations. These filings give context on capital raising activities, stockholders’ equity levels, and the company’s responses to Nasdaq’s continued listing requirements.
The company’s proxy statement on Form DEF 14A offers additional detail on corporate governance, director elections, equity incentive plans, and the selection of the independent registered public accounting firm. For investors tracking executive compensation structures, board oversight, and shareholder voting matters, the proxy materials are a primary reference.
On Stock Titan, users can access these STRATA filings alongside AI-powered summaries that highlight key points from lengthy documents, such as revenue composition, non-GAAP measures like adjusted EBITDA, and updates on reimbursement or litigation. The platform also surfaces real-time 8-Ks and other new submissions from EDGAR, helping users follow developments such as financing transactions, regulatory notices, and strategic disclosures without reading every page manually.
For those interested in trading dynamics and governance, Form 4 insider transaction reports and related ownership disclosures, when available, can be reviewed to see how STRATA’s officers, directors, or significant shareholders are transacting in SSKN shares. Together, these filings provide a detailed regulatory record of STRATA Skin Sciences’ financial condition, strategic direction, and compliance as a public dermatology device company.
Strata Skin Sciences, Inc. furnished a new investor presentation, dated December 2025, for investors and analysts. The company posted this presentation on its website and attached it as Exhibit 99.1 to a current report. The material is provided under a section that means it is being furnished, not filed, so it is not subject to certain liability provisions and will only be incorporated into other documents if specifically referenced.
STRATA Skin Sciences (SSKN)11/17/2025, the director sold three blocks of common stock: 5,500 shares at $1.32, 7,200 shares at $1.34, and 1,394 shares at $1.36. On 11/18/2025, the same person purchased 2,168 shares at $1.40 and 2,832 shares at $1.41. After these transactions, the director held 8,766 shares of STRATA Skin Sciences common stock with direct ownership.
STRATA Skin Sciences furnished an 8-K to announce it issued a press release with results for the third fiscal quarter ended September 31, 2025. The press release is included as Exhibit 99.1.
The disclosures under Item 2.02 and Item 7.01, including Exhibit 99.1, are being furnished, not filed, which means they are not subject to Section 18 liability and are not incorporated into other filings unless specifically referenced.
STRATA Skin Sciences (SSKN) called its 2025 Annual Meeting for December 10, 2025 at 9:00 a.m. local time in Horsham, PA. Stockholders of record as of October 13, 2025, when 5,268,708 shares of common stock were outstanding, may vote in person, by mail, online, or by telephone.
The agenda includes: electing five directors; approving an amendment to the 2016 Omnibus Incentive Plan to add 520,000 shares, bringing the total reserved to 1,476,249 shares, which the company states equals approximately 26.1% of outstanding shares as of May 12, 2025; and ratifying the appointment of CBIZ CPAs P.C. as independent registered public accounting firm for the year ending December 31, 2025.
Beneficial ownership is concentrated among several holders, including Accelmed Partners LP at 34.55%, 22NW Fund, LP at 15.32%, and Nantahala Capital Management, LLC at 9.68% (as of March 31, 2025). The board reports a majority of independent directors and active audit and compensation/governance committees. The company’s pay-versus-performance disclosure shows a net loss of $10,086 thousand in 2024 and a TSR value of $20.00 on an initial $100 investment.
STRATA Skin Sciences, Inc. filed preliminary proxy materials for its 2025 Annual Meeting, set for December 10, 2025, 9:00 a.m. local time, at its Horsham, PA offices. Stockholders of record as of October 13, 2025 (5,268,708 shares outstanding) may vote.
Agenda items include: electing five directors; and approving an amendment to the 2016 Omnibus Incentive Plan to add 520,000 shares, bringing total plan reserves to 1,476,249 shares, which the company states is approximately 26.1% of outstanding common stock as of May 12, 2025. The materials also note ratification of CBIZ CPAs P.C. as independent auditor for the year ending December 31, 2025.
Internet/telephone voting must be received by 11:59 p.m. EST on December 9, 2025. A quorum requires at least one-third of outstanding shares represented. Beneficial owners should follow their broker’s instructions to vote.
STRATA Skin Sciences updated its at-the-market equity program. The company filed a new prospectus supplement dated September 26, 2025 under its effective Form S-3 (File No. 333-283418), allowing registered “at-the-market” offerings of up to $11.0 million of common stock through Ladenburg Thalmann under an existing Equity Distribution Agreement.
The filing also includes a legal opinion from Stevens & Lee, P.C. as Exhibit 5.1 and related consent as Exhibit 23.1. This administrative step keeps the ATM facility current for potential future sales pursuant to the shelf registration.
STRATA Skin Sciences amended its prospectus supplement to update its at-the-market offering capacity under its Equity Distribution Agreement with Ladenburg Thalmann. The company may offer and sell shares of common stock with an aggregate offering price of up to $392,254 from time to time through Ladenburg acting as sales agent.
This cap reflects the Form S-3 General Instruction I.B.6 limit tied to the company’s public float. The filing cites an aggregate market value of non‑affiliate holdings of $8,889,292, based on 4,077,657 non‑affiliate shares at a price of $2.83 as of September 2, 2025. During the prior 12 months, the company sold $3,454,336 of securities under the same registration statement. Shares outstanding were 5,684,508 as of October 14, 2025. Any shares sold under the program would provide cash proceeds to the company, less sales agent fees.
Strata Skin Sciences reported it remains out of compliance with Nasdaq’s minimum $2,500,000 stockholders’ equity requirement. Nasdaq accepted the company’s plan and granted an extension until February 16, 2026 to regain compliance.
The company is evaluating actions discussed with Nasdaq. If compliance is not regained by the deadline, the common stock could become subject to delisting, though the company would be permitted to request a hearing, which would stay any suspension or delisting action during the process.
Strata Skin Sciences, Inc. offers up to $1,035,358 of common stock in an at-the-market offering to be sold from time to time through Ladenburg as sales agent. The company will use net proceeds for general corporate purposes, including working capital. The number of shares sold and gross proceeds will vary with market price and demand because sales occur at prevailing market prices under placement notices delivered to Ladenburg. The prospectus supplement references risk factors and incorporated SEC reports for additional detail and lists the types of securities the company may issue, including common and preferred stock, various debt securities, warrants, rights and units. Governance provisions and preferred stock terms are described in outline form, and detailed terms for any series of securities will be set in applicable prospectus supplements.
Strata Skin Sciences, Inc. Schedule 13G discloses that CVI Investments, Inc. and its investment manager Heights Capital Management, Inc. together report beneficial ownership of 365,849 shares, representing 6.9% of the outstanding common stock (based on 5,268,708 shares outstanding per the Company prospectus supplement). The filing shows no sole voting or dispositive power and records shared voting and dispositive power over all reported shares. Heights Capital is identified as investment manager and authorized agent for CVI Investments via a limited power of attorney.
FAQ
What is the current stock price of Strata Skin Sciences (SSKN)?
What is the market cap of Strata Skin Sciences (SSKN)?
